Table 2. The outcomes of the TOT procedure and the change of overactive bladder symptoms and questionnaire at 3 months, 1,2 and 3 years.
| Pre-op | 3 month | P value | 1 year | 2 years | 3 years | P value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICIQ-SF score | 17.1±2.7 | 4.9 ± 6.2 | <0.001* | 5.3 ±6.7 | 7.4 ± 7.6 | 8.7 ±8.2 | <0.001¥ | |||||
| OAB-V8 score | 22.7 ± 7.1 | 10.5 ± 9.1 | <0.001† | 11.4 ± 9.5 | 12.3 ±9.9 | 14.6 ± 9.9 | <0.001¥ | |||||
| SEAPI score | 28.2 ±8.8 | 5.8 ±8.7 | <0.001* | 6.5 ±9.6 | 8.7 ± 11.2 | 10.0 ± 11.8 | <0.001¥ | |||||
| IIQ7 score | 15.0 ±5.2 | 3.1 ± 4.5 | <0.001* | 3.4 ±4.9 | 4.6 ± 5.9 | 6.5 ±7.1 | <0.001¥ | |||||
| Clinically improvement in QoL(SEAPI) (n/total, %) | 84/104, 80.7 | 83/104, 79.8 | 51/75, 68.0 | 30/49, 61.2 | 1. vs 2. yr 0.031# 2. vs 3. yr 0.250# | |||||||
| Postoperative satisfaction rates (n/Total, %) | 89/104, 85.5 | 87/104, 83.6 | 56/75, 74.6 | 35/49, 71.4 | 1. vs 2. yr 0.039# 2. vs 3. yr 0.500# | |||||||
| 3 months | 1 year | 2 years | 3 years | |||||||||
| n | % | n | % | n | % | n | % | |||||
| Outcomes | ||||||||||||
| Objective cure | 100 | 96.2 | 99 | 95.2 | 68 | 90.7 | 39 | 79.6 | ||||
| Subjective cure | 59 | 56.7 | 55 | 52.8 | 38 | 50.6 | 17 | 34.6 | ||||
| Symptoms | ||||||||||||
| Urgency | ||||||||||||
| Cured | 56 | 53,8 | 52 | 50,0 | 34 | 45,3 | 16 | 32,7 | ||||
| Better | 27 | 26,0 | 30 | 28,8 | 24 | 32,0 | 15 | 30,6 | ||||
| Same | 16 | 15,4 | 16 | 15,4 | 12 | 16,0 | 11 | 22,4 | ||||
| Worsened | 5 | 4,8 | 6 | 5,8 | 5 | 6,7 | 7 | 14,3 | ||||
| Total | 104 | 104 | 75 | 49 | ||||||||
| Urgency incontinence | ||||||||||||
| Cured | 63 | 60,6 | 59 | 56,7 | 40 | 53,3 | 18 | 36,7 | ||||
| Better | 20 | 19,2 | 23 | 22,1 | 17 | 22,7 | 13 | 26,5 | ||||
| Same | 17 | 16,3 | 18 | 17,3 | 14 | 18,7 | 11 | 22,4 | ||||
| Worsened | 4 | 3,8 | 4 | 3,8 | 4 | 5,3 | 7 | 14,3 | ||||
| Total | 104 | 104 | 75 | 49 | ||||||||
| Frequency | ||||||||||||
| Cured | 37 | 43,0 | 35 | 40,7 | 22 | 34,9 | 11 | 27,5 | ||||
| Better | 30 | 34,9 | 30 | 34,9 | 26 | 41,3 | 17 | 42,5 | ||||
| Same | 16 | 18,6 | 18 | 20,9 | 10 | 15,9 | 6 | 15,0 | ||||
| Worsened | 3 | 3,5 | 3 | 3,5 | 5 | 7,9 | 6 | 15,0 | ||||
| Total | 86 | 86 | 63 | 40 | ||||||||
| Nocturia | ||||||||||||
| Cured | 21 | 26,6 | 20 | 25,3 | 16 | 28,1 | 9 | 23,1 | ||||
| Better | 38 | 48,1 | 37 | 46,8 | 22 | 38,6 | 13 | 33,3 | ||||
| Same | 19 | 24,1 | 21 | 26,6 | 16 | 28,1 | 12 | 30,8 | ||||
| Worsened | 1 | 1,3 | 1 | 1,3 | 3 | 5,3 | 5 | 12,8 | ||||
| Total | 79 | 79 | 57 | 39 | ||||||||
*
Wilcoxon test
¥
ANOVA for Repeated Measures
†
Paired-Samples T-test
#
McNemar test (significant level of 0.017)
ICIQ-SF: International Consultation on Incontinence Questionnaire - Short Form, UDI-6: Urogenital Distress Inventory, OAB-V8: 8-item overactive bladder questionnaire, SEAPI: Incontinence Quality of Life Score questionnaire, IIQ7: The incontinence impact questionnaire-7